Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecified Health Condition 2: J454- Moderate persistent asthma Health Condition 3: M179- Osteoarthritis of knee, unspecified Health Condition 4: M059- Rheumatoid arthritis with rheumatoid factor, unspecified
Conditions
Interventions
Intervention1: Standard therapy + Magnesium Glycinate: 400mg - oral - once daily for 1 year
Control Intervention1: standard therapy + Placebo: 400mg - oral - once daily - for one year
Sponsors
M Maneesh Kumar Reddy
Eligibility
Inclusion criteria
Inclusion criteria: Patients with hypomagnesemia (serum magnesium level below 1.6mg/dl) Age (above 18 years) Individuals willing to participate in study Patients on standard therapy managing their inflammatory disorders (Asthma, COPD, Rheumatoid Arthritis and Osteoarthritis) Both sex
Exclusion criteria
Exclusion criteria: Known allergy to the any of the drug investigated Currently using any magnesium related products Having any psychiatric illness Administering drugs that affect ADME of investigation product Presence of alcohol or drug dependence Evidence of renal or hepatic impairment Pregnant and lactating women Participation in any other clinical trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| C-Reactive Protein, Inflammatory Markers (TNF Alpha, IL-6, IL-10), Disease Activity ScoreTimepoint: 0 month, 3 month, 6 month, 9 month, 12 month | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum Magnesium, Quality of Life, Medication Adherence, Adverse Drug Reactions, FEV1/FVC (Asthma & COPD), Ligamentous Laxity (Osteoarthritis), Rheumatoid Factor (Rheumatoid Arthritis) Timepoint: 0 month, 3 month, 6 month, 9 month, 12 month | — |
Countries
India
Contacts
Public ContactDr MG Rajanandh
SRM College of Pharmacy
Outcome results
None listed